Platelets are anucleate cells known for their essential function in hemostasis and formation of thrombi under pathologic conditions. In recent years, strong evidence emerged demonstrating the critical involvement of platelets in inflammatory processes including acute ischemic stroke (AIS), which is one of the leading causes of death and disability worldwide. Recanalization of the occluded brain artery to reconstitute cerebral blood flow is the primary goal in the treatment of stroke patients. However, despite successful reperfusion many patients show progression of infarct sizes, a phenomenon referred to as ischemia/reperfusion injury (I/RI). Cerebral I/RI involves both thrombotic as well as inflammatory pathways acting in concert to cause tissue damage, defining AIS as a prototypic thrombo-inflammatory disease. Currently used antiplatelet drugs applied to AIS patients eventually increase the risk of partially life-threatening hemorrhages, making more targeted pharmacological intervention necessary. Experimental evidence indicates that inhibition of platelet surface receptors that regulate initial platelet adhesion and activation might be suitable targets in thrombo-inflammatory settings, while inhibitors of platelet aggregation are not. In this review, we will summarize the recent developments in elucidating the role of the main platelet receptors in AIS and discuss their potential as pharmaceutical targets. Furthermore, we will also briefly discuss the important platelet-triggered intrinsic coagulation pathway with the pro-inflammatory kallikrein–kinin system in the context of ischemic stroke.
Platelets are essential players in hemostasis and contribute to the maintenance of vascular integrity under physiological conditions. Dysregulated platelet activation and aggregation in combination with local coagulation can cause formation of vessel-occluding thrombi under pathological conditions, resulting in ischemia and infarction of affected tissues. Depending on the site of thrombus formation, this can cause life-threatening disease states such as myocardial infarction, deep vein thrombosis, potentially leading to pulmonary embolism or stroke.1–4 Besides the well-known functions in hemostasis and thrombosis, platelets got into focus in the context of inflammatory disease processes, like host defense or post-ischemic tissue damage in multiple organ systems. For example, platelets are known to be involved in leukocyte recruitment to sites of inflammation by direct interaction with inflammatory cells as well as the release of pro-inflammatory cytokines.5,6 Moreover, other substances released by platelets are able to mediate the generation of pro-inflammatory bradykinin via the kallikrein-kinin pathway. These atypical platelet functions, linking thrombotic cascades to innate immunity, are based on essentially different mechanisms than those utilized in normal hemostasis and are involved in pathological processes now referred to as thrombo-inflammation, a word that was initially coined to describe the pathomechanisms that drive neuronal damage in the setting of ischemic stroke.7

Amongst all neurological diseases, stroke accounts for the largest proportion of disability and deaths worldwide. Only 20% of all strokes are caused by intracranial hemorrhage (ICH). The majority is due to cerebral ischemia, caused by a thromboembolic occlusion of a major cerebral artery, leading to acute ischemic stroke (AIS).8,9 Thus, the primary goal of therapy is the recanalization of occluded vessels to restore cerebral blood flow. This is achieved either by chemical thrombolysis with the tissue plasminogen activator (tPA) or, more recently, by mechanical thrombectomy (MT). Although fast intervention by either of the techniques increased the rate of restored blood flow markedly, the number needed to treat to benefit (NNTB) is still high. Within the first 3 to 4.5 hours after ischemic stroke, the NNTB for thrombolytic treatment with tPA is around 7 and around 2 for MT, which is most likely a consequence of the higher recanalization rates achieved by MT, demonstrating the necessity of restoring blood flow.10 This is also in line with the observation that patients neither eligible for pharmacological nor mechanical removal of the thrombus or in which the therapeutic procedure fails, occlusion persists, and infarct volume rapidly increases.11,12 This pathological state is known as permanent ischemia. The eligibility of pharmacological recanalization is dependent on different factors and exclusion criteria, e.g., the stage of infarct development, previous ICH, low platelet count (<100,000/µL), or myocardial infarction in the last 3 months.11 Although MT is an effective alternative for patients ineligible for tPA treatment, absence of proximal intracranial occlusion, hospital arrival outside the eligible time window, low baseline National Institutes of Health Stroke Scale (NIHSS) score, and posterior circulation cerebral ischemia are the four most common contraindications for MT.13 However, even despite successful recanalization, infarct sizes often continue to grow, and the underlying molecular mechanisms are only poorly understood. This phenomenon is referred to as ischemia/reperfusion injury (I/RJ) and can also be seen in other organ systems like heart, liver, and kidney.14–16 Such infarct growth after successful recanalization is also prominently observed in experimental models of stroke, most notably in the transient middle cerebral artery occlusion (tMCAO) model. This model utilizes a very thin filament, which is brought into the middle cerebral artery (MCA) via the internal carotid artery to induce vessel occlusion for a defined time period (typically

**Introduction**

Platelets are essential players in hemostasis and contribute to the maintenance of vascular integrity under physiological conditions. Dysregulated platelet activation and aggregation in combination with local coagulation can cause formation of vessel-occluding thrombi under pathological conditions, resulting in ischemia and infarction of affected tissues. Depending on the site of thrombus formation, this can cause life-threatening disease states such as myocardial infarction, deep vein thrombosis, potentially leading to pulmonary embolism or stroke.1–4 Besides the well-known functions in hemostasis and thrombosis, platelets got into focus in the context of inflammatory disease processes, like host defense or post-ischemic tissue damage in multiple organ systems. For example, platelets are known to be involved in leukocyte recruitment to sites of inflammation by direct interaction with inflammatory cells as well as the release of pro-inflammatory cytokines.5,6 Moreover, other substances released by platelets are able to mediate the generation of pro-inflammatory bradykinin via the kallikrein-kinin pathway. These atypical platelet functions, linking thrombotic cascades to innate immunity, are based on essentially different mechanisms than those utilized in normal hemostasis and are involved in pathological processes now referred to as thrombo-inflammation, a word that was initially coined to describe the pathomechanisms that drive neuronal damage in the setting of ischemic stroke.7

Amongst all neurological diseases, stroke accounts for the largest proportion of disability and deaths worldwide. Only 20% of all strokes are caused by intracranial hemorrhage (ICH). The majority is due to cerebral ischemia, caused by a thromboembolic occlusion of a major cerebral artery, leading to acute ischemic stroke (AIS).8,9 Thus, the primary goal of therapy is the recanalization of occluded vessels to restore cerebral blood flow. This is achieved either by chemical thrombolysis with the tissue plasminogen activator (tPA) or, more recently, by mechanical thrombectomy (MT). Although fast intervention by either of the techniques increased the rate of restored blood flow markedly, the number needed to treat to benefit (NNTB) is still high. Within the first 3 to 4.5 hours after ischemic stroke, the NNTB for thrombolytic treatment with tPA is around 7 and around 2 for MT, which is most likely a consequence of the higher recanalization rates achieved by MT, demonstrating the necessity of restoring blood flow.10 This is also in line with the observation that patients neither eligible for pharmacological nor mechanical removal of the thrombus or in which the therapeutic procedure fails, occlusion persists, and infarct volume rapidly increases.11,12 This pathological state is known as permanent ischemia. The eligibility of pharmacological recanalization is dependent on different factors and exclusion criteria, e.g., the stage of infarct development, previous ICH, low platelet count (<100,000/µL), or myocardial infarction in the last 3 months.11 Although MT is an effective alternative for patients ineligible for tPA treatment, absence of proximal intracranial occlusion, hospital arrival outside the eligible time window, low baseline National Institutes of Health Stroke Scale (NIHSS) score, and posterior circulation cerebral ischemia are the four most common contraindications for MT.13 However, even despite successful recanalization, infarct sizes often continue to grow, and the underlying molecular mechanisms are only poorly understood. This phenomenon is referred to as ischemia/reperfusion injury (I/RJ) and can also be seen in other organ systems like heart, liver, and kidney.14–16 Such infarct growth after successful recanalization is also prominently observed in experimental models of stroke, most notably in the transient middle cerebral artery occlusion (tMCAO) model. This model utilizes a very thin filament, which is brought into the middle cerebral artery (MCA) via the internal carotid artery to induce vessel occlusion for a defined time period (typically

**Schlüsselwörter**

- Thrombozyten
- Thrombozytenrezeptoren
- Schlaganfall
- Thrombo-inflammation
- FXII
60 minutes) followed by its removal, thereby mimicking the pathology of ischemia due to thromboembolism with subsequent reperfusion injury after recanalization.\textsuperscript{17}

Permanent ischemia and I/RI in hospitalized stroke patients have been tightly connected to neuro-inflammatory processes including the infiltration of immune cells, especially T cells, into the infarcted brain tissue. This has been observed in experimental models of stroke as well as in human patients.\textsuperscript{7,18–21} In addition, neutrophilic granulocytes, the first immune cells appearing at sites of inflammatory brain injuries, are implicated in further damaging the blood–brain barrier by releasing proteolytic enzymes, reactive oxygen species, and neutrophil extracellular traps (NETs). Notably, the interaction of platelets with neutrophilic granulocytes has been shown to induce the formation of NETs in various inflammatory conditions, and might also play a role in AIS.\textsuperscript{22,23} The exact contribution of neutrophilic granulocytes to ischemic brain damage and I/RI, however, is not fully elucidated and are controversially discussed (reviewed in Strecker et al.\textsuperscript{24}).

Already in the 1980s, the accumulation of platelets and factors of the coagulation system at sites of cerebral infarction was recognized.\textsuperscript{25,26} The contribution of platelets and infiltrating immune cells, especially T cells, to the progression of cerebral I/RI is now supported by several experiments.\textsuperscript{19} The finding that the closely intertwined action of thrombotic and inflammatory mechanisms drives post-ischemic cerebral infarct progression leads to the concept of ischemic stroke being a thrombo-inflammatory disease. Strikingly, the treatment of patients with classical antiplatelet drugs like aspirin or clopidogrel after recanalization does not reliably reduce infarct growth in all patients, probably because they have only limited effects on thrombo-inflammatory processes. In contrast, these treatments emerged as rather unfavorable, since they often result in ICH.\textsuperscript{27,28} Hence, more targeted pharmacological intervention to limit thrombo-inflammatory activity of platelets is needed to prevent patients from I/RI while minimizing the risk of ICH.

In this review we will summarize physiological functions of the main platelet receptors and then discuss their role in the thrombo-inflammatory disease setting of AIS and their potential as pharmaceutical targets, based on experimental and, in part, clinical studies. Furthermore, we will briefly discuss the connection between the important platelet-triggered factor XII (FXII)-driven intrinsic coagulation pathway and the pro-inflammatory kallikrein–kinin system (KKS) in the context of ischemic stroke, emphasizing the direct involvement of platelets in mediating inflammatory processes by inducing the production of the pro-inflammatory compound bradykinin.

**Platelets and Hemostasis**

At sites of vascular injury, the first contact of platelets with the exposed extracellular matrix (ECM) is mediated by the receptor complex glycoprotein (GP)Ib–V–IX (\textsuperscript{Fig. 1}). This receptor complex, more precisely its GPIb\textsubscript{α} subunit, interacts with von Willebrand factor (vWF) which derives from endothelial cells or is released from the \(\alpha\)-granules of platelets and is then captured at sites of endothelial damage or activation.\textsuperscript{29,30} This first interaction leads to an initial tethering and deceleration of
the platelets under high shear as prevailing, e.g., in stenosed arteries, but does by itself not mediate firm adhesion or thrombus growth. However, this slower “rolling” along the vessel wall allows other receptors that mediate platelet activation to interact with their corresponding ligands. One of those is the immunoglobulin-like receptor GPVI, which binds to collagen, but also other ligands such as fibrin. Due to its low affinity for collagen, this interaction does not lead to stable adhesion by itself but rather mediates cellular activation via the immunoreceptor tyrosine-based activation motif (ITAM) in the associated Fc receptor (FcR) γ-chain, triggering a tyrosine phosphorylation cascade which leads to activation of effector enzymes and Ca\(^{2+}\) mobilization. These processes result in the activation of the platelets and the release of secondary mediators like adenosine diphosphate (ADP) and serotonin as well as the production of thromboxane A\(_2\) (TxA\(_2\): Fig. 1). Additionally, platelet activation results in scissor-blade-mediated exposure of negatively charged phosphatidylserine on the platelet surface, providing a platform for the assembly of two major coagulation factor complexes and subsequent thrombin production. Simultaneously exposed tissue factor contributes to initiates the local generation of thrombin. Together with ADP and TxA\(_2\), thrombin further augments platelet activation via signaling through G-protein coupled receptors. Another major activation receptor is the hem-ITAM bearing C-type lectin-like receptor 2 (CLEC-2), of which the only known endogenous ligand is podoplanin, a membrane glycoprotein not normally expressed within the vasculature. All these outside-in signals result in the conformational change of the most prominent adhesion receptor in platelets, integrin \(\alpha\)IIb\(\beta\)3 (GPIIb/IIIa) from an inactive to a high affinity state for its multiple ligands, leading to firm platelet adhesion, aggregation, and thrombus formation. Another consequence of platelet activation is the release of inorganic polyphosphate (PolyP) triggering activation of coagulation factor XII (FXII) which represents the starting point of the intrinsic coagulation pathway and the KKS (Fig. 1).

### Targeting GPIIb/IIIa in Ischemic Stroke

Once platelets are activated through their surface agonist receptors, an inside-out signaling cascade leads to a conformational change of GPIIb/IIIa from a low affinity state to an active high affinity binding state, which allows firm adhesion to the ECM by binding multiple ligands such as vWF, fibronectin, and vitronectin. Furthermore, GPIIb/IIIa facilitates aggregate formation by bridging neighboring platelets through fibrinogen and vWF (Fig. 1). Its essential role in thrombus formation suggests that GPIIb/IIIa might be an attractive target to combat acute ischemic disorders. Currently, there are three pharmacological inhibitors for GPIIb/IIIa used in the clinical routine: the chimeric humanized monoclonal antibody fragment 7E3 Fab abciximab, eptiplateb, and tirofiban, which is a nonpeptide fibrinogen mimetic. The beneficial effect of GPIIb/IIIa inhibition is well established in acute coronary syndrome patients undergoing percutaneous coronary intervention, where I/RI is a known pathological process leading to increased infarct sizes as well. In a study where rat hearts were subjected to I/RI and transfused with platelets from patients with acute myocardial infarction (AMI) ex vivo, it was shown that those hearts which received platelets from AMI patients co-incubated with abciximab developed less myocardial injury after ischemia and reperfusion than those receiving untreated platelets. Also in patients with AMI, the clinical outcome is markedly improved when abciximab is applied in combination with heparin or mechanical removal of the thrombus compared with patients who are not co-treated with abciximab. These findings suggest that I/RI in AMI is worsened by activated platelets and anti-GPIIb/IIIa treatment attenuates these effects. In the case of ischemic stroke, however, the therapeutic potency of GPIIb/IIIa-targeting drugs is discussed controversially. Early experimental studies utilizing the tMCAO model in mice and a thromboembolic model in rabbits, where a blood clot was injected into the cerebral arterial system, showed a beneficial effect of GPIIb/IIIa blockade by the nonpeptide SDZ GPI 562 and the synthetic cyclic nonpeptides TP9201 and SM-20302 on neurological outcome and infarct sizes in the setting of ischemic stroke. Strikingly, these studies showed that GPIIb/IIIa inhibition even led to a dampened hemorrhagic effect of I\(\alpha\)P treatment or exhibited no I\(\alpha\)CH in therapeutic doses. As a potential explanation for this surprising finding, the authors suggested that this might be due to the prevention of reoccurring microthrombi when GPIIb/IIIa was blocked. Contradictory to that, mouse models of tMCAO revealed that inhibition of GPIIb/IIIa by F(ab\(_2\)) fragments of the function-blocking antibody JON/A leads to severe I\(\alpha\)CH and eventually to death of the treated mice. More importantly, however, those mice that did not develop severe I\(\alpha\)CH showed similar infarct sizes to control-treated animals regardless of the dose of antibody. Furthermore, these effects held true when older mice or mice with certain comorbidities were subjected to the same experimental setup. Similar consequences of anti-GPIIb/IIIa administration were observed in different clinical studies as well. In an international, randomized, placebo-controlled, double-blind study, the administration of abciximab led to severe intracranial bleeding in a significant number of patients after 5 days regardless of the timepoint of intravenous injection after stroke, onset of stroke, or wake-up stroke. Thus, the study was terminated in phase III after inclusion of 808 patients (Table 1).

Tirofiban is frequently used to prevent vessel re-occlusion after mechanical removal of thrombi or stenting, which can cause vascular damage. However, a prospective study of patients with ischemic stroke revealed that those receiving tirofiban had significantly higher risks of intracranial bleeding and poor outcome compared with control. Nonetheless, especially tirofiban is discussed controversially regarding its use in AIS patients, since some studies showed the safety and efficacy of this drug in patients with rescue stenting, using tirofiban alone or together with standard thrombolytic therapy. In conclusion, despite the high potency of anti-GPIIb/IIIa treatment in patients with AMI and some promising clinical studies using tirofiban in a certain subgroup of ischemic stroke patients, this receptor has to be
Table 1 Summary of the in vivo effects of interfering with the function of indicated platelet receptors and FXII in experimental stroke. Recent clinical data on AIS and ongoing trials illustrate the translational potential of the experimental results

<table>
<thead>
<tr>
<th>Main functions in hemostasis</th>
<th>GPIb</th>
<th>GPVI</th>
<th>FXII</th>
<th>CLEC-2</th>
<th>GPIb/IIIa</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tethering; deceleration of platelets at wound site</td>
<td>Interaction with collagen; platelet activation (granule release, activation of GPIb/IIIa); interaction with fibrin</td>
<td>Activated by released PolyP; starting point of intrinsic coagulation cascade</td>
<td>Supports aggregation</td>
<td>Firm adhesion, aggregation, and thrombus formation</td>
<td></td>
</tr>
</tbody>
</table>

**Experimental targeting strategy**

<table>
<thead>
<tr>
<th>Anti-GPIba Fab fragment (blockade of vWF binding site)</th>
<th>Anti-GPVI IgG (JAQ1—depletion of receptor)</th>
<th>GPVI-Fc fusion protein (Revacept)</th>
<th>FXIIa-inhibitors</th>
<th>Anti-CLEC-2 IgG (INU1—depletion of receptor)</th>
<th>Anti-GPIb/IIIa F(ab)2 fragment</th>
<th>Tirotifiban (fibrinogen mimetic)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-GPIb/IIIa F(ab)2 fragment</td>
<td>Anti-GPVI IgG</td>
<td>GPVI-Fc fusion protein (Revacept)</td>
<td>FXIIa-inhibitors</td>
<td>Anti-CLEC-2 IgG (INU1—depletion of receptor)</td>
<td>Anti-GPIb/IIIa F(ab)2 fragment</td>
<td>Tirotifiban (fibrinogen mimetic)</td>
</tr>
<tr>
<td>Anti-GPIb/IIIa F(ab)2 fragment</td>
<td>Anti-GPVI IgG</td>
<td>GPVI-Fc fusion protein (Revacept)</td>
<td>FXIIa-inhibitors</td>
<td>Anti-CLEC-2 IgG (INU1—depletion of receptor)</td>
<td>Anti-GPIb/IIIa F(ab)2 fragment</td>
<td>Tirotifiban (fibrinogen mimetic)</td>
</tr>
</tbody>
</table>

**Consequences on experimental stroke**

<table>
<thead>
<tr>
<th>Reduced infarct sizes</th>
<th>Improved neurological outcome</th>
<th>Reduced local inflammation</th>
<th>No intracranial hemorrhages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-GPVI IgG</td>
<td>Reduced infarct sizes</td>
<td>No intracranial hemorrhages</td>
<td>GPVI-Fc fusion protein</td>
</tr>
<tr>
<td>Reduced infarct and edema volumes</td>
<td>Reduced inflammatory response</td>
<td>Better cerebral perfusion with rtPA</td>
<td>Increased survival rate</td>
</tr>
<tr>
<td>No intracranial hemorrhages</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Clinical data on AIS**

<table>
<thead>
<tr>
<th>Polymorphisms in GPI BA gene are associated with ischemic stroke</th>
<th>GPI expression as predictive biomarker for cerebral ischemia</th>
<th>Humanized anti-GPVI Fab fragment (9O12)</th>
<th>Controversially discussed as potential biomarker for AIS</th>
<th>Positive correlation of sCLEC-2 plasma levels with stroke progression, recurrence of vascular events, and risk of death</th>
<th>Abciximab</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical efficacy of targeting GPIb to be elucidated</td>
<td>Phase II clinical trial: ongoing; patients with carotid artery thrombosis, TIA, stroke, and coronary artery disease</td>
<td>Phase II clinical trial: ongoing; AIS patients</td>
<td>Clinical efficacy of targeting FXII to be elucidated</td>
<td>Possible prognostic biomarker</td>
<td>Terminated phase III clinical trial: severe intracranial hemorrhages in patients with stroke</td>
</tr>
<tr>
<td>Controversially discussed as potential biomarker for AIS</td>
<td>Clinical efficacy of targeting FXII to be elucidated</td>
<td>Positive correlation of sCLEC-2 plasma levels with stroke progression, recurrence of vascular events, and risk of death</td>
<td>Possible prognostic biomarker</td>
<td>Terminated phase III clinical trial: severe intracranial hemorrhages in patients with stroke</td>
<td>Controversial data; intracranial hemorrhages and poorer outcome in AIS patients (prospective study); effective and safe in a subset of patients with rescue stenting</td>
</tr>
</tbody>
</table>

Abbreviations: AIS, acute ischemic stroke; GP, glycoprotein; vWF, von Willebrand factor; IgG, immunoglobulin G; rtPA, recombinant tissue plasminogen activator; TIA, transient ischemic attack; rHA-Infestin-4, recombinant human albumin-Infestin-4; rhC1-Inhibitor, recombinant human Cl-Inhibitor; CLEC-2, C-type lectin-like 2; sCLEC-2, soluble CLEC-2.
considered as unreliable, yet druggable target in the therapy of ischemic stroke (\textit{\textasciitilde} Table 1). Very importantly, these data provide strong evidence that platelet aggregation may not be of major significance for thrombo-inflammation and immune cell recruitment in the infarcted brain, implicating that other platelet-dependent mechanisms are responsible for the pathological progress of I/RI in AIS.

**Targeting GPIba\textendash}vWF Interaction in Ischemic Stroke**

The subunit GPIba of the GPIb–vWF receptor complex directly binds to immobilized vWF but also multiple other ligands such as P-selectin and macrophage antigen 1 (Mac-1), which can be found on the surface of immune cells, e.g., neutrophil granulocytes. Furthermore, components of the coagulation cascade like FXI, FXII, and FIIa (thrombin) are known ligands of GPIba.\textsuperscript{2} In experimental models of tMCAO, the blockade of GPIba by intravenous injection of Fab-fragments of the function-blocking antibody p0p/B, reduced infarct sizes to approximately 40\% compared with control animals. This protective effect was also reflected by an improved neurological outcome and sustained reperfusion, while no intracerebral hemorrhages were observed (\textit{\textasciitilde} Table 1).\textsuperscript{50,56} Notably, these beneficial effects were observed regardless of whether the treatment was given 1 hour before or 1 hour after tMCAO, indicating not only a protective but also a potential therapeutic effect of GPIba blockade.\textsuperscript{50} In addition, another study utilizing the tMCAO model demonstrated that p0p/B Fab treatment attenuates the local inflammation as shown by reduced monocyte and CD4 T cell infiltration into the infarcted brain and diminished expression of pro-inflammatory cytokines like interleukin (IL) 6, IL-1β, and tumor necrosis factor-α.\textsuperscript{57} Similar results were obtained using a mouse model, where the ectodomain of GPIba is replaced by the ectodomain of the human IL-4 receptor (IL4Ra/GPiba) leading to abolished ligand binding without the loss of the receptor complex.\textsuperscript{58,59} These findings emphasize the relevance of GPIba for the progression of I/RI in stroke. Conversely, also mice lacking the main ligand of GPIba, vWF, developed smaller infarcts and displayed a better neurological outcome in the tMCAO model as compared with their respective controls without showing signs of ICH. Of note, reconstitution of plasma vWF by hydrodynamic gene transfer was sufficient to revert the protection, showing that these results were specifically attributable to the loss of plasma vWF.\textsuperscript{60} Furthermore, vWF derived from platelets in chimeric mice has been shown to be sufficient to revert the protective effect of vWF deficiency in the tMCAO model, showing that even a small fraction of vWF is sufficient to increase infarct volumes and worsen neurological outcome.\textsuperscript{61} Other studies focused on the protease A disintegrin and metalloprotease with thrombospondin type 1 repeats 13 (ADAMTS13), which cleaves vWF into smaller, less active fragments thereby modulating the total activity of vWF. Mice deficient in ADAMTS13 (\textit{Adams13} \textsuperscript{-/-}) showed significantly increased infarct volumes and worsened neurological outcome after tMCAO.\textsuperscript{62,63} In line with these results, treatment of wild-type mice with recombinant human ADAMTS13 (r-hu-ADAMTS13) before reperfusion resulted in reduced infarct volumes compared with untreated animals after experimental cerebral ischemia, indicating that ultra-large vWF multimers are of particular pathogenic relevance for thrombo-inflammatory damage in the acutely ischemic brain.\textsuperscript{64}

The intracellular signaling cascade triggered by GPIba\textendash}vWF interactions is not fully understood. It is known that the intracellular domain of GPIba is associated with the act-binding protein 14–3–3ζ and various signaling molecules like phosphatidylinositol kinase 3 (PI3K), Src-related tyrosine kinases, GTPase-activating proteins, and tyrosine phosphatases have been proposed to be activated by ligand binding to GPIba. This downstream signaling is reported to induce weak intracellular Ca\textsuperscript{2+} mobilization and activation of αIIbβ3 integrin.\textsuperscript{65} The lipid signaling enzyme phospholipase D 1 (PLD1) may play a key role in GPIba-dependent platelet activation since platelets derived from mice deficient for PLD1 (\textit{Pld1} \textsuperscript{-/-}) showed defective adhesion on vWF-coated surfaces under high shear conditions.\textsuperscript{65} Furthermore, it has been shown that PLD1 deficiency resulted in reduced platelet-dependent leukocyte recruitment under inflammatory conditions in in vivo models of carotid artery injury and venous thrombosis.\textsuperscript{66} The significant role of both PLD isoforms, PLD1 and PLD2, for thrombus formation was reflected by defective α-granule release and prevention of vessel occlusion in a model of FeCl\textsubscript{3}-induced arteriolar thrombosis in mice deficient for both isoforms.\textsuperscript{57} Moreover, pharmacological inhibition of PLD with 5-fluoro-2-indolyldes-chlorohalopemide (FIPI) in mice leads to delayed thrombus formation and vessel occlusion in two in vivo models of arterial thrombosis, the FeCl\textsubscript{3}-induced injury of the carotid artery, and the mesenteric artery thrombosis model, suggesting an antithrombotic effect of FIPI. Importantly, FIPI-treated mice showed significantly reduced infarct volumes, ischemic lesions, and better neurological outcome after subjection to tMCAO compared with untreated mice, without developing intracerebral hemorrhages, pointing to a promising and safe treatment of AIS.\textsuperscript{68} Besides evidence of the role of GPIba\textendash}vWF interactions and resulting signaling in murine models of ischemic stroke, studies in human stroke patients support the experimental data (\textit{\textasciitilde} Table 1). There are several known genetic variations in the \textit{GPIBA} gene. The -5 T/C dimorphism in the untranslated Kozak sequence has been recognized for altering the expression level of GPIba. In addition, a Thr/Met change in the coding region and a variable number of tandem repeat sequence have been shown to affect the protein structure. All of them have been associated with the development of ischemic stroke in patients carrying certain variants of the mentioned polymorphisms.\textsuperscript{69}

**Targeting GPVI in Ischemic Stroke**

GPVI is the main MK/platelet collagen receptor and mediates cellular activation of platelets. Ligand binding initiates signaling through the receptor-associated Fcγ-chain dimers, which bear an ITAM. This results in rapid rearrangement of the cytoskeleton, Ca\textsuperscript{2+} mobilization, granule release, and activation of integrin αIIbβ3 (GPIIbIIIa).\textsuperscript{33,70} In mice, the in vivo application of the monoclonal anti-GPVI antibody JAQ1 leads...
to the depletion, i.e., irreversible loss of GPVI in circulating platelets. This results in a GPVI knockout-like phenotype and abolished collagen responses for at least two weeks. Using intravital fluorescence microscopy in a model of carotid artery injury in mice, Massberg et al. showed that GPVI depletion (JAQ1 IgG) or its functional inhibition (JAQ1 Fab) resulted in reduced platelet tethering at the injured vessel wall and significantly diminished stable platelet capture and aggregation. Furthermore, platelets of GPVI-depleted mice failed to adhere to collagen under static as well as under flow conditions and the animals were protected from experimental lethal pulmonary thromboembolism. More recently, two studies have demonstrated that GPVI also interacts with fibrin, thereby contributing to thrombus growth and stabilization. Altogether, these studies highlight GPVI as one major receptor in arterial thrombus formation. In the tMCAO model, GPVI depletion leads to a significant reduction of infarct volumes, although to a lesser extent than GPIbα inhibition (pPp/B-Fab). Strikingly, no IC was observed in GPIbα−/− or GPVI-depleted mice, indicating that GPVI might be a promising pharmacological target for the treatment of acute stroke. This is supported by a very recent study utilizing the tMCAO model, in which mice were treated with JAQ1 and concomitantly received human recombinant tPA (rtPA), the standard treatment of ischemic stroke patients. Of note, depletion of GPVI in this co-treatment still exhibited its protective effect on infarct progression and improved neurological outcome in the acute phase after tMCAO, but caused no bleeding complications.

Ligand binding triggers cross-linking of GPVI, bringing its FcRγ chains and the Src family tyrosine kinases (SFKs) Fyn and Lyn into proximity. This initiates a tyrosine phosphorylation cascade starting with the spleen tyrosine kinase (Syk), which in turn phosphorylates the adapter protein linker for activation of T cells (LAT) and finally leads to the activation of effector enzymes, most notably PLCγ2 and phosphoinositide 3-kinase (PI3K). In the tMCAO model, mice genetically lacking Syk in platelets (Syk−/−, P4−/−) showed significantly reduced infarct sizes and better neurological scores compared with the corresponding control. Notably, the same outcome was observed in wild-type mice after oral administration of the Syk inhibitor, BI1002494, which exhibited its protective effect also when administered after removal of the filament, i.e., during the reperfusion phase. In both cases, no intracerebral hemorrhages were observed. Hence, pharmacological Syk inhibition appears to be a potentially safe therapeutic intervention to protect patients from arterial thrombosis and infarct growth after successful recanalization and restored perfusion.

Src-like adapter proteins (SLAP and SLAP2) are structurally similar to SFKs but lack the kinase domain and seem to inhibit ITAM-receptor-mediated platelet activation, since mice deficient for both proteins exhibited platelet hyperresponsiveness upon GPVI stimulation in vitro. In line with the neurological protective effects of GPVI blockade or inhibition of downstream signaling molecules, genetically SLAP1/2 double-deficient mice displayed markedly increased infarct volumes and worsened neurological outcomes after tMCAO.

The absence of notable bleeding phenotypes when interfering with GPVI-ITAM signaling in the tMCAO model of ischemic stroke suggests that GPVI might be a potent and safe therapeutic target to prevent cerebral infarct progression in patients with successful recanalization. A possible role of GPVI in acute stroke in humans was shown in a cohort study including patients with transient ischemic attack (TIA) and stroke as well as patients with non-ischemic events as controls. Here, the authors showed that GPVI expression of platelets from TIA and stroke patients was significantly elevated compared with controls. Furthermore, they revealed a positive correlation between GPVI levels and relative risk of stroke and, notably, a poorer clinical outcome. By providing a cut-off value of GPVI expression, they suggested GPVI as a predictive biomarker for the occurrence of cerebral ischemia.

GPVI expression can be downregulated by ectodomain shedding by the metalloproteinases ADAM10 and ADAM17, thereby releasing soluble GPVI (sGPVI) into the blood plasma. A clinical study showed significantly increased plasma levels of sGPVI in patients with acute stroke, implicating GPVI shedding in the acute phase of the disease. Revacet, a dimeric GPVI-Fc fusion protein, which inhibits the GPVI–collagen interaction, is the first clinically tested GPVI inhibitor. Under conditions of ischemic stroke, Revacet treatment in mice resulted in better cerebral reperfusion when given with concomitant rtPA injection. Furthermore, the compound improved neurological score and survival rate and also decreased infarct and edema volumes compared with control animals without causing intracranial bleeding. Additionally, several indicators of inflammatory cell infiltration and reperfusion damage were reduced upon Revacet treatment, e.g., the detection of immunoglobulin G (IgG), infiltrated macrophages, transforming growth factor β, and platelet-derived growth factor in brain sections. Currently, Revacet is being tested in phase II clinical trials in patients with carotid artery stenosis, TIA, or stroke (NCT 01645306) and in patients with coronary artery disease (NCT 03312855).

Another promising pharmacological compound interfering with GPVI function is the humanized Fab fragment ACT017 (9O12) which inhibits collagen-induced platelet aggregation in a dose-dependent manner. When tested in vivo in cynomolgus monkeys (Macaca fascicularis), the antibody derivative did not induce thrombocytopenia or deplete the receptor from platelets and it had no effect on normal hemostasis. Since phase I clinical trials in healthy volunteers proofed that ACT017 is a safe and well-tolerated compound showing favorable pharmacokinetic/pharmacodynamic properties, a phase II clinical trial in patients with AIS is currently in progress (NCT 03803007).

### Targeting CLEC-2 in Ischemic Stroke

C-type lectin-like receptor 2 (CLEC-2) is a platelet receptor that contributes to platelet activation through a signaling pathway similar to GPVI. The only known ligands for CLEC-2 are the snake venom rhodocytin as well as the endogenous ligand podoplanin. On resting platelets CLEC-2 exists as a homo-dimerized receptor, which forms...
 oligomers upon ligand binding.\textsuperscript{86} Contrary to GPVI-induced signaling, the initial phosphorylation of the central tyrosine in the hem-ITAM of CLEC-2 is mediated by the tyrosine kinase Syk and not Fyn or Lyn, which act more downstream in this signaling cascade, that otherwise uses similar effector and adapter molecules as GPVI, resulting in strong platelet activation.\textsuperscript{87} The interaction of podoplanin on lymphatic endothelial cells and neuroepithelial cells with CLEC-2 is essential to maintain the separation of lymphatic and blood vessels and prevent ICH during development, respectively.\textsuperscript{88,89} Therefore, global CLEC-2 deficiency in mice is lethal at the embryonic or neonatal stage. Those mice exhibit a disorganized vessel structure and impaired lymphatic clearance with blood-lymphatic mixing as well as impaired vascularization of the brain. In these processes, CLEC-2-dependent signaling in platelets seems to be critical, since MK/platelet-specific deletion of CLEC-2, Syk, or SLP-76 resulted in the same blood-lymphatic mixing phenotype and hemorrhaging within the brain as the constitutive knockout of CLEC-2.\textsuperscript{90,91}

It is likely that this receptor might also play an important role in hemostasis and thrombosis, because platelets are fully activated and form aggregates upon stimulation with the CLEC-2 agonist rhodocytin and form thrombi on podoplanin-coated surfaces under flow.\textsuperscript{19,85,92} Indeed, platelet-specific loss of CLEC-2 upon treatment of mice with the antibody INU1 resulted in significant defects in platelet aggregate formation under flow in vitro, which translated into defective thrombus formation in a model of FeCl\textsubscript{3}-induced mesenteric artery injury and into prolonged bleeding times.\textsuperscript{93} Later on, the involvement of CLEC-2 in thrombus formation ex vivo and in vivo was corroborated in a study using fetal liver cell chimeric mice, with a genetic CLEC-2 deficiency,\textsuperscript{88} while another study found no significant role of CLEC-2 for platelet aggregate formation at arteriolar shear.\textsuperscript{94} More recently, a critical role for CLEC-2 was also observed in a mouse model of deep vein thrombosis, where the platelet specific knockout of the receptor prevented full vessel occlusion.\textsuperscript{95} Of note, bleeding times in those mice were not significantly altered compared with the corresponding controls.

Overall, these studies have provided compelling evidence that CLEC-2 contributes to platelet function in hemostasis and thrombosis, making it a potential antithrombotic target. Interestingly, this function of CLEC-2 appears to be independent of its hemITAM,\textsuperscript{96} indicating that it acts more as an adhesion receptor rather than a receptor for platelet activation in this setting.

Although pharmacological blockade of CLEC-2 appears to be a promising antithrombotic strategy, caution is warranted since the combined loss of GPVI and CLEC-2 leads to dramatically prolonged bleeding times as well as to abrogated thrombus formation, demonstrating functional redundancy of the two (hem)ITAM receptors.\textsuperscript{97} Furthermore, recent studies have suggested a complex role of CLEC-2 beyond classical hemostasis (reviewed in Rayes et al.\textsuperscript{13}), e.g., in maintaining vascular integrity under inflammatory conditions,\textsuperscript{98,99} and in addition it was demonstrated that the podoplanin–CLEC-2 axis inhibits inflammation in mouse models of sepsis and lung injury.\textsuperscript{100,101} Therefore, the potential targeting of CLEC-2 in patients must be considered very carefully. Given that no patients with CLEC-2 deficiency are known to date, the relevance of this receptor in ischemic stroke in human might be questionable and needs further investigation, especially because there are no experimental studies addressing the role of CLEC-2 in stroke. Nonetheless, plasma levels of soluble CLEC-2 (sCLEC-2) could recently be positively correlated with stroke progression, recurrence of vascular events, and risk of death in patients with AIS, making sCLEC-2 a promising prognostic marker for AIS (\textsuperscript{2}Table 1).\textsuperscript{102,103}

### FXII-Bradykinin in Ischemic Stroke

Another hallmark of platelet activation besides the conformational change of GPIIb/IIIa to its high affinity state is the release of granules which store a plethora of mediators that further augment thrombotic and inflammatory processes. Among those, negatively charged inorganic PolyPs have a key role in the initiation of both coagulation and inflammation.\textsuperscript{40} (\textsuperscript{1}Fig. 1). Upon contact with PolyP, coagulation factor FXII is turned into FXIIa representing the starting point of the intrinsic coagulation pathway. In addition, FXIIa cleaves plasma kallikrein (PK) which by itself activates FXII.\textsuperscript{40} Furthermore, the activated KKS leads to the liberation of the pro-inflammatory mediator bradykinin, which contributes to vessel dilatation, neutrophil recruitment, and increased vascular permeability upon binding to B1 and B2 receptors (B1R and B2R) on endothelial cells and neurons.\textsuperscript{30,104} Thus, the contact pathway provides a link between platelet-mediated activation of the intrinsic coagulation pathway via FXII and pro-inflammatory processes involving the KKS (\textsuperscript{1}Fig. 1). It was long believed that FXII is dispensable for blood clot formation since patients with hereditary deficiency of FXII display no bleeding phenotype, neither do mice with genetic knockout of FXII. However, FXII-deficient mice were protected from vessel occlusion in different in vivo models of arterial thrombosis as well as from collagen/epinephrine-induced pulmonary thromboembolism, showing that FXII is critical for pathological thrombus formation but not for hemostasis.\textsuperscript{105} Importantly, FXII-deficient mice or wild-type mice treated with the specific FXIIa-inhibitor recombinant human albumin-Infestin-4 (rHA-Infestin-4) showed marked protection from ischemic brain injury in the tMCAO model without signs of ICH.\textsuperscript{106,107} These results suggest that FXII could be a promising therapeutic target for the treatment of AIS patients. Of note, a small cohort study of 22 patients suffering from ischemic stroke showed a significant activation of the tissue KKS,\textsuperscript{108} implicating that FXII might also be involved in stroke development in humans. The link of FXII to the pro-inflammatory KKS is further highlighted by studies investigating B1R, FXIIa, and the PK blocker C1-inhibitor in the context of AIS. Mice deficient for B1R displayed smaller infarct sizes, less edema formation, better neurological outcome, and increased long-term survival compared with wild-type mice when subjected to the tMCAO model. Furthermore, ameliorated post-ischemic
inflammation, reflected by decreased infiltration of neutrophilic granulocytes, macrophages, and T cells into the ischemic brain was seen in B1R-deficient mice. Similar results were obtained by pharmacological blockade of B1R with R-715 in a dose-dependent manner. The C1-inhibitor is a serine protease classically known as a physiological inhibitor of the complement system. Moreover, it can block FXIIa and PK, thereby preventing leukocyte recruitment during inflammation. In the tMCAO model, mice and rats treated with recombinant human C1-inhibitor (rhC1-inhibitor) 1 hour after induction of stroke showed significantly reduced infarct volumes, better neurological outcome, and improved survival (→Table 1). This protective effect was mostly attributable to the protection of blood–brain barrier function reflected by less edema formation, attenuated inflammation, and prevention of tissue damage-triggered, secondary microvascular thrombosis. Furthermore, directly interfering with the KKS system by constitutively knocking out PK in mice (PK⁻⁻) had favorable effects in the tMCAO model. Twenty-four hours after removal of the filament and reperfusion, PK⁻⁻ mice were protected from brain infarction and showed improved neurological outcome, which was reverted when the animals had been reconstituted with human PK. The same was true for pharmacological interference with PK by administration of a neutralizing PK-specific antibody. Like C1-inhibitor-treated mice, PK-deficient mice showed similar anti-thrombotic and anti-inflammatory effects as well as no significant intracranial bleedings. These results support the concept that both thrombotic and inflammatory pathways operate in concert and are mechanistically linked to drive neuronal damage in the setting of AIS.

The other principal substrate of FXIIa is FXI, which in turn activates the intrinsic pathway of coagulation. Pretreatment of mice with the antibody 14E11, which inhibits activation of FXI by FXIIa, resulted in improved reperfusion, reduced infarct sizes, and less fibrin accumulation compared with untreated mice following tMCAO, without inducing ICH. This further underlines the relevance of FXII in AIS, making it a druggable and potentially a safe target to combat AIS. However, clinical data on the relevance of FXI and FXII in patients in the context of ischemic stroke are not yet conclusive. Some studies showed higher FXI levels in patients with acute stroke and a correlation with poorer prognosis. Others could not find any differential regulation of FXI or FXII levels between different subtypes of acute cerebrovascular events, making FXI or FXII poor biomarkers to identify patients at risk of ischemic stroke. Nonetheless, experimental data suggest that the FXII–kallikrein–kinin pathway might be a safe molecular target to reduce brain damage in the setting of AIS.

Trials to elucidate the potential of interfering with the FXII–kallikrein–kinin pathway to treat AIS patients are currently ongoing (→Table 1). In addition, a phase II clinical trial deals with direct inhibition of FXIIa by oral administration of BMS-986177 in combination with aspirin and clopidogrel to prevent recurrence of thrombotic events leading to secondary stroke in ischemic stroke patients (NCT03766581).

Conclusions

While the central function of platelets in hemostasis and thrombosis has been firmly established for decades, there is now an increasing awareness that these cells orchestrate a large variety of other physiological and pathological processes, most notably inflammation and innate immunity. Thereby, mechanisms and receptor functions that are critical in thrombosis and hemostasis are not necessarily suitable targets in thrombo-inflammatory diseases (→Fig. 1 and →Table 1), highlighting the need to carefully assess efficacy of anti-platelet drugs in the respective experimental and clinical settings. GPib as well as GpVI have emerged as promising and potentially safe therapeutic targets in the treatment of thrombosis as well as AIS (→Table 1). Pharmacologic interference with these receptors improved neurological outcome and reduced the inflammatory response in experimental stroke models without increasing the bleeding risk.

One central conclusion of several preclinical stroke studies may be that the thrombotic occlusion of the microvasculature in the reperfused brain territory is likely the consequence rather than the cause of ischemic tissue damage. This is strongly supported by the observation that inhibition of platelet aggregation is not protective in these models, despite abrogating microvascular thrombosis. Based on this hypothesis, one might predict that more or less all approaches aiming at the inhibition of classical platelet-dependent thrombus formation may prevent or reduce the initial occurrence of stroke but not the resultant I/R. Interfering with the thrombo-inflammatory activity of platelets might on the other hand provide protection from infarct progression without the major side effect of existing anti-thrombotic agents, namely the increased bleeding risk. Of note, the exact contribution of platelet receptors and signaling pathways to inflammation and maintenance of vascular integrity seems to be determined by the affected tissue and vasculature as well as the pathogenic stimulus. This means that approaches leading to an improved outcome in AIS patients will not necessarily show beneficial effects in other thrombo-inflammatory disease settings affecting other organs.

Clearly, further studies are needed to better understand the mechanistic implications as well as the tissue- and stimulus-specific functions of platelet receptors, signaling pathways, and effector function in thrombo-inflammatory disease conditions. This will be of pivotal importance for finding safe and effective treatment strategies for patients with thrombotic and/or thrombo-inflammatory disorders.

Conflict of Interest

The authors declare that they have no conflict of interest.

Acknowledgment

The work was supported by the Deutsche Forschungsgemeinschaft (project number 374031971–CRC/TR 240).

References

Platelets in Ischemic Stroke


21 Yilmaz G, Arumugam TV, Stokes KY, Granger DN. Role of T lymphocytes and interferon-gamma in ischemic stroke. Circulation 2006;113(17):2105–2112


This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.


